Flibanserin (Addyi) Overdose and Accidental Excess Dose: What Women Need to Know

What Is Flibanserin and How Does It Work?

Flibanserin is a non-hormonal prescription medication approved by the FDA in August 2015 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not a hormone. It is not a "female Viagra." It acts on your brain, not your genitals.

The Neuropharmacology Behind HSDD Treatment

HSDD is understood, at least in part, as an imbalance between excitatory signals (dopamine, norepinephrine) and inhibitory signals (serotonin) in the brain's sexual-response circuitry. Flibanserin is a mixed serotonin receptor agonist-antagonist. It acts as a 5-HT1A agonist and 5-HT2A antagonist, which is thought to decrease serotonergic inhibition while modestly increasing dopamine and norepinephrine activity in the prefrontal cortex.

This dual action distinguishes it from antidepressants. SSRIs raise serotonin globally and are well-known to reduce libido. Flibanserin targets specific receptor subtypes to try to restore what researchers describe as the motivational salience of sexual desire, the internal "wanting" rather than the physical "arousal."

What the Evidence Actually Shows

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014, randomized 1,090 premenopausal women with HSDD to flibanserin 100 mg at bedtime or placebo for 24 weeks. Women on flibanserin reported approximately 0.5 more satisfying sexual events per month compared with placebo. Scores on the Female Sexual Function Index desire domain and distress improved statistically but modestly. The effect size is real and statistically significant, but small in absolute terms.

Three pooled Phase 3 trials showed flibanserin produced approximately 0.5 to 1.0 additional satisfying sexual events per month above placebo. Be cautious with any source that describes this as a dramatic change. Women's-health clinicians often discuss these numbers candidly at the time of prescribing.

Understanding the Overdose Risk

The central danger with flibanserin is not just taking too many tablets. It is the way the drug's pharmacology amplifies when the dose is exceeded, when alcohol is co-ingested, or when CYP3A4 inhibitors are present. Each of these scenarios can transform a modest CNS-active compound into a serious toxicological event.

Why the CNS Depression Deepens So Quickly

Flibanserin is metabolized almost entirely by CYP3A4 and CYP2C19 in the liver. Its half-life is approximately 11 hours. When you take a second tablet, take it earlier in the day than prescribed, or combine it with a CYP3A4 inhibitor (fluconazole, certain antibiotics, grapefruit juice), plasma concentrations can rise dramatically above the therapeutic window. The CNS depression that is merely a bedtime side effect at 100 mg becomes clinically significant at higher exposures.

Sedation, dizziness, and orthostatic hypotension are dose-dependent. In overdose, the spectrum extends to syncope, obtundation, and, when alcohol is involved, potentially life-threatening blood pressure drops.

Alcohol: The Most Common Overdose Amplifier

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) specifically because of the alcohol-flibanserin interaction. A dedicated interaction study showed that even two standard alcoholic drinks consumed with flibanserin caused hypotension and syncope in approximately 20% to 25% of participants, a rate far above background. Some women in that study had syncope within 30 minutes of drinking. The REMS requires you to abstain from all alcohol while taking flibanserin.

This is not a conservative precaution. It is a pharmacokinetic and pharmacodynamic reality.

Signs and Symptoms of Flibanserin Overdose

Knowing what an overdose looks like matters, because the sedation can progress quickly enough that a woman may not be able to call for help herself.

Early Symptoms (First 1 to 2 Hours)

• Severe, sudden sleepiness or difficulty staying awake
• Significant dizziness when standing (orthostatic hypotension)
• Nausea and vomiting
• Slurred speech
• Feeling faint or lightheaded even while lying down

Progressive Symptoms (2 to 6 Hours)

• Inability to be woken fully
• Blood pressure reading below 90/60 mmHg
• Slow, irregular heartbeat
• Confusion or disorientation that is worse than expected for the dose

Severe / Emergency Presentation

• Loss of consciousness
• Syncope with injury (fall)
• Breathing that is slow or labored
• No response to voice or sternal rub

Any progression beyond early symptoms requires emergency services. Do not drive yourself to the emergency department if you are symptomatic.

What to Do Immediately

Step 1: Call Poison Control First If the Person Is Awake

The US Poison Control number is 1-800-222-1222. Available 24 hours a day, seven days a week. The specialist will assess the amount taken, timing, alcohol co-ingestion, and any other drugs, and advise you on whether to go to an emergency department or monitor at home.

Step 2: Call 911 If There Is Any Loss of Consciousness

If the woman is not waking up, is breathing irregularly, or has fallen and been injured, call 911 before anything else. Put her in the recovery position (on her side) if she is unconscious and breathing, to reduce aspiration risk.

Step 3: Information to Have Ready

When you speak to Poison Control or emergency responders, gather:

• The number of tablets taken and their strength (flibanserin is available only as 100 mg)
• The approximate time the tablets were taken
• Whether alcohol was consumed, how much, and when
• Any other medications taken in the past 24 hours, especially antifungals, antibiotics, antihistamines, or other CNS depressants
• Any known liver disease (flibanserin is contraindicated in hepatic impairment)

Step 4: Do Not Induce Vomiting

Unless specifically directed by Poison Control. Aspiration of vomit in a sedated person is a serious risk.

How Overdose Is Managed in an Emergency Department

There is no antidote for flibanserin overdose. Management is entirely supportive. Emergency clinicians focus on stabilizing the cardiovascular and respiratory systems while the drug is metabolized and cleared.

Supportive Care Measures

Standard ED management for flibanserin toxicity includes:

• Continuous cardiac monitoring and pulse oximetry
• IV access and isotonic fluid resuscitation for hypotension
• Airway protection; intubation if the woman cannot protect her airway
• Vasopressors (typically norepinephrine) if fluids fail to restore blood pressure
• Activated charcoal if the ingestion was within one hour and the airway is protected

Given flibanserin's 11-hour half-life, symptomatic women may need to be observed for 12 to 24 hours even after initial stabilization.

Drug Interactions That Complicate Treatment

If a woman has also taken a CYP3A4 inhibitor, flibanserin plasma levels may be four to seven times higher than expected for the dose alone. The label specifically contraindicates moderate-to-strong CYP3A4 inhibitors with flibanserin. Emergency clinicians should be told of any recent use of:

• Fluconazole (Diflucan), a common antifungal prescribed frequently to women
• Clarithromycin or erythromycin
• Ketoconazole
• HIV protease inhibitors
• Grapefruit or grapefruit juice consumed in quantity

Pregnancy, Lactation, and Contraception

Flibanserin is approved only for premenopausal women, and pregnancy is not a minor consideration. The FDA label does not assign a traditional A/B/C/D/X letter category under the post-2015 labeling system, but the safety profile in pregnancy is essentially unknown.

Pregnancy

There are no adequate and well-controlled studies of flibanserin in pregnant women. Animal reproductive studies showed no clear teratogenicity at doses approximating the human therapeutic exposure, but animal data rarely predicts human outcomes with CNS-active agents. Given the absence of any established benefit in pregnancy (HSDD treatment is not an obstetric indication) and the theoretical risk of CNS effects in a developing fetus, flibanserin should be discontinued before attempting conception.

If you become pregnant while taking flibanserin, stop the medication and contact your prescriber and obstetrician promptly.

Lactation

It is not known whether flibanserin passes into human breast milk. The drug is lipophilic and CNS-active, which means transfer into milk is biologically plausible. FDA advises that the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need and potential infant risks. Given the modest benefit of flibanserin overall and the unknown infant exposure, most women's-health clinicians advise against using flibanserin while breastfeeding.

Contraception

Because flibanserin is only approved for premenopausal women who are not pregnant, your prescriber should confirm your contraception status. Reliable contraception is advisable while taking this medication, particularly because many women using flibanserin are in their active reproductive years. Hormonal contraceptives do not significantly alter flibanserin pharmacokinetics, so combined oral contraceptives, patches, rings, IUDs, or implants are all compatible.

Accidental Double Dosing: A Specific Scenario

The most common form of excess exposure is not an intentional overdose. It is forgetting whether you already took your bedtime dose and taking a second one.

What to Do If You Accidentally Take Two Tablets

If you realize you have taken two 100 mg tablets within a short window, do not panic, but do act:

1. Call Poison Control (1-800-222-1222) and describe exactly what happened.
2. Stay in bed and do not drink alcohol for any reason.
3. Do not drive or operate machinery for at least 12 hours.
4. Have someone stay with you to monitor your alertness and blood pressure if possible.
5. Seek emergency care if you develop pronounced sedation, syncope, or irregular heartbeat.

The risk from a single accidental double dose in a woman without liver disease who has not consumed alcohol is lower than a full intentional overdose, but it is not trivial. Plasma concentrations will approximately double, which can push CNS effects from "manageable bedtime drowsiness" into clinically significant sedation.

Who Flibanserin Is Right For, and Who It Is Not

The FDA approved flibanserin specifically for premenopausal women with acquired, generalized HSDD. Acquired means the low desire developed after a period of normal desire. Generalized means it occurs across partners and situations, not only in specific contexts.

Appropriate Candidates

• Premenopausal women with a formal HSDD diagnosis confirmed by a qualified clinician
• Women who have ruled out relationship distress, depression, and medication-induced low desire as primary drivers
• Women who understand and can commit to strict alcohol abstinence during treatment
• Women who are not pregnant, not planning pregnancy immediately, and not breastfeeding
• Women who are not taking moderate-to-strong CYP3A4 inhibitors

Who Should Not Take Flibanserin

The following groups face unacceptable risk-benefit profiles:

• Postmenopausal women: Not FDA-approved for this group. Evidence in postmenopausal women is limited, and the FDA has not found sufficient data to extend the indication. A 2016 ACOG committee opinion notes that sexual dysfunction management should be individualized by life stage.
• Women with hepatic impairment: Contraindicated. Even mild liver disease meaningfully raises flibanserin exposure and overdose risk.
• Women who drink alcohol regularly: The REMS program exists for this reason. If total abstinence is not realistic, this drug is not the right choice.
• Women taking CYP3A4 inhibitors: Including fluconazole, a medication prescribed extremely commonly to women for vulvovaginal candidiasis. If you have a yeast infection requiring fluconazole, flibanserin must be paused and Poison Control or your prescriber should advise on the minimum washout before resuming.
• Women on SSRIs or SNRIs: CNS depression is compounded. The combination is not absolutely contraindicated but requires careful discussion with your prescriber.

A Note on PCOS and Hormonal Conditions

Women with PCOS who have low desire sometimes receive a HSDD diagnosis. Androgen excess in PCOS is not correlated with increased sexual desire in all women, and in some, PCOS-related psychological distress, body image concerns, and hormonal dysregulation suppress desire. Before prescribing flibanserin to a woman with PCOS, clinicians should confirm that the PCOS itself is optimally managed, because addressing insulin resistance, androgen excess, and mood is likely to yield a larger benefit than a drug with a modest absolute effect size.

The Perimenopause Question

Flibanserin is not approved for perimenopausal or postmenopausal women, but this distinction creates a clinical gap worth naming directly. Many women who develop HSDD are in perimenopause, a phase during which they are still menstruating (and therefore technically premenopausal by some definitions) but experiencing significant hormonal fluctuation.

The FDA label language specifies "premenopausal," and the BEGONIA trial enrolled premenopausal women with a mean age of approximately 36 years. Women in their mid-to-late 40s with irregular cycles were largely excluded from or underrepresented in the Phase 3 program. This is a genuine evidence gap. If you are in your mid-40s with irregular periods and declining libido, the cause may well be perimenopause-related estrogen fluctuation rather than the neurobiological profile that flibanserin targets.

The Menopause Society recommends addressing genitourinary syndrome of menopause, sleep disruption, and vasomotor symptoms before attributing low desire in perimenopausal women to primary HSDD. Hormone therapy or local vaginal estrogen may produce a more meaningful improvement in this life stage.

Preventing Accidental Overdose at Home

Practical steps that reduce the risk before any emergency occurs:

• Keep flibanserin in its original labeled bottle with the cap tightly closed, in a location separate from other nighttime medications.
• Use a pill organizer with a daily tracker if you take multiple bedtime medications.
• Set a phone alarm labeled "Addyi taken" immediately after each dose so you never have to guess.
• Tell anyone in your household that the small pink tablet is prescription only and should not be touched by children or by anyone for whom it was not prescribed.
• Store it away from alcohol. The visual proximity of a pill bottle and a wine glass on the same nightstand is a real-world risk factor.
• If you are prescribed fluconazole for a yeast infection (which is common), call your prescriber the same day. You will likely need to pause flibanserin for the duration of fluconazole treatment plus a washout period. Do not attempt to manage this timing on your own.

Flibanserin tablets can be appealing to a child who sees a small pink pill. The REMS program does not include specific pediatric overdose data, because there are no controlled studies in children. If a child ingests flibanserin, call Poison Control immediately regardless of the amount. Children's smaller body weight and different metabolic capacity mean even a single tablet could cause significant CNS depression.

The REMS Program: Why Your Pharmacy Has to Be Certified

The FDA's Addyi REMS requires that every prescriber and every dispensing pharmacy complete a certification process. Prescribers must counsel patients on the alcohol interaction and document that counseling. Pharmacies must distribute a Medication Guide at each dispensing.

This is not bureaucratic formality. The REMS exists because, in pre-approval trials, the alcohol interaction produced hypotension and syncope at a rate that regulators judged unacceptable without structured risk communication. Understanding why your prescriber asks about your drinking habits and why your pharmacist reviews the interaction every time you refill is part of using this medication safely.